At Dennis Partners, we know regulatory recruiting. We are committed to creating and maintaining partnerships with our clients while upholding the highest standards of professionalism and ethics. Our team interacts within the marketplace on a daily basis, giving us the ability to locate, screen, and recommend exceptional individuals to your firm. We know how to identify the top performers. Our strength is partnering with you and your business to develop a solution and meet demands for growth while improving efficiency. Let our advanced expertise find the top professionals in the industry to provide a competitive edge to your company.
We have your specialization covered
Contract-to-hire evaluation process
We're on your side
Complete back office support
Our process is cost-effective
Dennis Partner’s focus on only regulatory affairs searches gives them a very good sense of the market, the available talent, and who matches the role. They worked with us diligently to find the right candidate and we ended up making an exceptional hire.
We take the time to evaluate your needs beyond a job description
We identify top talent from our research and competitive analysis
We analyze the talent to match candidates on a deeper level
We go beyond the hire by offering extensive post placement services
Does your company have immediate top-tier talent needs?
Meet Our Team
This was a relatively quiet regulatory news week when compared to the past few weeks. Here is my summary of the top stories to follow: The FDA approved Puma Biotechnology’s neratinib for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer. https://www.firstwordpharma.com/node/1488664 The FDA approved Gilead’s VOSEVI, a three-drug combination of[…]
Lots of regulatory news this week including one new molecular entity approval, an Advisory Committee thumbs-up for Novartis’s CAR-T program, a reversal for Amicus, and several new orphan drug designations. Here’s my summary of the top regulatory stories for this week: J&J subsidiary Janssen Biotech has secured approval from the FDA for its Tremfya (guselkumab)[…]
The June Employment Situation released by the Bureau of Labor Statistics showed that the U.S. economy added 222,000 jobs. This far exceeded analysts’ expectations of just over 170,000 jobs. The current unemployment rate is 4.4 percent. Healthcare added 37,000 jobs, with 25,000 of these roles increasing in ambulatory healthcare services, and 12,000 in hospitals. Despite[…]
According to a June New York Times article, “We may be closer to full employment than it seemed.” Based on the May jobs report, the source asserts the possibility that this is as good as it will get for the United States labor market. Why? Slowed job growth with 121,000 new positions as the three-month[…]
Here are the top ten regulatory news stories to follow this week: Arbor Pharmaceuticals and Debiopharm International announced that the FDA has approved Triptodur for the treatment of pediatric patients 2 years and older with central precocious puberty. Full Story Here Bristol-Myers Squibb’s ORENCIA (abatacept) received FDA approval for treatment of active Psoriatic Arthritis (PsA) in adults. Orencia has been previously[…]
I am posting a bit early this week due to the long holiday weekend. Here are the top regulatory news stories to follow this week: FDA’s biosimilars lead Leah Christl said last week at DIA’s annual conference in Chicago that she expects interchangeable biosimilars will come to market within the next two years: http://raps.org/Regulatory-Focus/News/2017/06/26/27969/FDA-Interchangeable-Biosimilar-Approvals-Expected-Within-2-Years/ […]
This has been a busy week with a few big announcements from the FDA, the approval of one NME, and several other program approvals. Here are a few of the top stories for regulatory professionals to follow: FDA Commissioner Scott Gottlieb vowed to eliminate the backlog of orphan drug designation requests and said he will[…]
One of the things that I discuss with candidates as we start the process of planning their next Strategic Career Move is the importance of being proactive. Don’t wait to start your job search until you are in a situation where you must find a new position. You are a much stronger candidate while you[…]
This week the FDA granted Breakthrough Therapy designation to multiple programs, granted an Orphan Drug designation and also rejected a biosimilar application. Here is a summary of the top 10 regulatory stories to follow this week: Proteon Therapeutics received FDA Breakthrough Therapy Designation for Vonapanitase for chronic kidney disease. Full Story Here The FDA’s Oncologic[…]
Here are the top nine regulatory news stories this week: The European Commission (EC) approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-based therapy. Full Story Here Gilead Sciences plans to submit a new triple combination HIV therapy for FDA approval[…]